These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 8804488)

  • 1. Prognostic indicators for response to therapy and survival in patients with metastatic renal cell cancer treated with interferon alpha-2 beta and vinblastine.
    Papadopoulos I; Rudolph P; Weichert-Jacobsen K; Thiemann O; Papadopoulou D
    Urology; 1996 Sep; 48(3):373-8. PubMed ID: 8804488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon alfa and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma.
    Kriegmair M; Oberneder R; Hofstetter A
    Urology; 1995 May; 45(5):758-62. PubMed ID: 7747370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers.
    Mani S; Todd MB; Katz K; Poo WJ
    J Urol; 1995 Jul; 154(1):35-40. PubMed ID: 7539867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of adjuvant immunotherapy after radical nephrectomy and prognostic factors in pT3N0M0 renal cell carcinoma.
    Jeon SH; Chang SG; Kim JI
    Anticancer Res; 1999; 19(6C):5593-7. PubMed ID: 10697624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sarcomatoid differentiation as a prognostic factor for immunotherapy in metastatic renal cell carcinoma.
    Kwak C; Park YH; Jeong CW; Jeong H; Lee SE; Moon KC; Ku JH
    J Surg Oncol; 2007 Mar; 95(4):317-23. PubMed ID: 17066434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histologic subtype of metastatic renal cell carcinoma predicts response to combined immunochemotherapy with interleukin 2, interferon alpha and 5-fluorouracil.
    Herrmann E; Brinkmann OA; Bode ME; Bierer S; Köpke T; Bögemann M; Hertle L; Wülfing C
    Eur Urol; 2007 Jun; 51(6):1625-31; discussion 1631-2. PubMed ID: 17113215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
    Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
    J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors for renal cell carcinoma with tumor thrombus extension.
    Klatte T; Pantuck AJ; Riggs SB; Kleid MD; Shuch B; Zomorodian N; Kabbinavar FF; Belldegrun AS
    J Urol; 2007 Oct; 178(4 Pt 1):1189-95; discussion 1195. PubMed ID: 17698087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie.
    Negrier S; Escudier B; Lasset C; Douillard JY; Savary J; Chevreau C; Ravaud A; Mercatello A; Peny J; Mousseau M; Philip T; Tursz T
    N Engl J Med; 1998 Apr; 338(18):1272-8. PubMed ID: 9562581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant interleukin-2, interferon-alpha, and 5-fluorouracil immunochemotherapy after radical nephrectomy for locally advanced renal cell carcinoma.
    Hong SK; Kwak C; Lee SE
    Urology; 2005 Sep; 66(3):518-22. PubMed ID: 16140069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study.
    Samuels BL; Hollis DR; Rosner GL; Trump DL; Shapiro CL; Vogelzang NJ; Schilsky RL
    Clin Cancer Res; 1997 Nov; 3(11):1977-84. PubMed ID: 9815587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group.
    Gleave ME; Elhilali M; Fradet Y; Davis I; Venner P; Saad F; Klotz LH; Moore MJ; Paton V; Bajamonde A
    N Engl J Med; 1998 Apr; 338(18):1265-71. PubMed ID: 9562580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metastatectomy prior to immunochemotherapy for metastatic renal cell carcinoma.
    Lee SE; Kwak C; Byun SS; Gill MC; Chang IH; Kim YJ; Hong SK
    Urol Int; 2006; 76(3):256-63. PubMed ID: 16601390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does radical nephrectomy with immunochemotherapy have any superiority over embolization alone in metastatic renal cell carcinoma? A preliminary report.
    Demirci D; Tatlişen A; Ekmekçioğlu O; Ozcan N; Kaya R
    Urol Int; 2004; 73(1):54-8. PubMed ID: 15263794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens.
    Miyake H; Sakai I; Muramaki M; Kurahashi T; Takenaka A; Fujisawa M
    Int J Urol; 2009 May; 16(5):465-71. PubMed ID: 19467119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there a role for adjuvant immunochemotherapy after radical nephrectomy in pT2-3N0M0 renal cell carcinoma?
    Migliari R; Muscas G; Solinas A; Melis M; Ionta MT; Massidda B; Usai E
    J Chemother; 1995 Jun; 7(3):240-5. PubMed ID: 7562021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma.
    Clark PE; Hall MC; Miller A; Ridenhour KP; Stindt D; Lovato JF; Patton SE; Brinkley W; Das S; Torti FM
    Urology; 2004 Jun; 63(6):1061-5. PubMed ID: 15183950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant alpha-interferon plus vinblastine in metastatic renal-cell cancer: analysis of response and survival in 58 evaluable patients.
    Bergerat JP; Ford J; Herbrecht R; Dufour P; Oberling F; Jacqmin D; Bollack C; Prevot G; Salze P; Jurascheck F
    Prog Clin Biol Res; 1990; 348():137-50. PubMed ID: 2385604
    [No Abstract]   [Full Text] [Related]  

  • 20. [Interferon and vinblastine in presumably operable metastases of renal carcinoma].
    Pizzocaro G; Piva L; Faustini M; Mangiarotti B; Nicolai N; Salvioni R; Milani A; Zanoni F
    Arch Ital Urol Androl; 1993 Apr; 65(2):177-80. PubMed ID: 8330064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.